Scholar Rock Holding Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Scholar Rock Holding şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-4.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-4.4%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Seeking Alpha • Jun 25

Scholar Rock: New Treatment Boost For SMA Patients -- With September PDUFA

Summary Scholar Rock Holding Corporation (SRRK) focuses on Apitegromab, a selective anti-latent myostatin antibody for Spinal Muscular Atrophy in patients aged 2 and above. The initial FDA BLA submission for Apitegromab was rejected, but SRRK has since resubmitted its BLA for review. The investment thesis centers on regulatory progress and the clinical potential of Apitegromab in addressing unmet needs in SMA. SRRK's future hinges on successful FDA approval and market adoption of its lead therapy. Read the full article on Seeking Alpha

Analiz Makalesi • Jun 21

Scholar Rock Holding (SRRK) Stock Could Be 14.1% Undervalued On Its SMA Narrative

Scholar Rock Holding (SRRK) stock has drawn investor attention after a recent move in its share price, with the company’s Nasdaq listing closing at $47.33 and showing mixed short and longer term return figures. See our latest analysis for Scholar Rock Holding. For context, Scholar Rock Holding’s recent 1-day share price return of 0.81% and 7-day share price return of 7.13% sit alongside a slightly weaker 30-day share price return, while its 1-year and 3-year total shareholder returns point to...

Yeni Anlatı • Mar 07

Muscle-Targeted SMA Therapies And Global Expansion Will Reshape Long-Term Outlook

Catalysts About Scholar Rock Holding Scholar Rock Holding focuses on developing muscle-targeted therapies for rare and severe neuromuscular diseases, led by its apitegromab program for spinal muscular atrophy and a broader anti myostatin pipeline. What are the underlying business or industry changes driving this perspective?

Seeking Alpha • Apr 17

Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade

Summary Scholar Rock Holding Corporation's lead candidate, apitegromab, has shown promising efficacy in treating SMA and is awaiting FDA and EMA approval, with a potential market launch by late 2025. Apitegromab could achieve blockbuster status with peak revenue potential >$2.5bn, especially based on its ability to build muscle mass in combo with gene therapies like Spinraza and Zolgensma. Scholar Rock's obesity therapy potential with apitegromab and GLP-1 RA combo presents a high-risk, high-reward scenario, with significant upside if Phase 2 data is positive. Despite financial challenges and potential dilution, I upgrade SRRK stock to a "Buy" due to its promising pipeline and undervalued stock price at $30. Read the full article on Seeking Alpha

Seeking Alpha • Jan 30

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

Summary Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Apitegromab is being explored in the phase 2 proof-of-concept EMBRAZE study, given alongside GLP-1 drugs to treat patients with obesity; Data from this trial is expected in Q2 of 2025. Positive data from the phase 2 EMBRAZE study would lead to IND of SRK-439 in Q3 of 2025 to target obesity and other cardiometabolic disorders. The global obesity drugs market is expected to reach $200 billion by 2031. Read the full article on Seeking Alpha

Seeking Alpha • Dec 24

Scholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High

Summary Scholar Rock's lead candidate, apitegromab, showed promising Phase 3 results in SMA, boosting shares by over 325%, with plans for regulatory submissions in the US and EU. Despite positive data, Scholar Rock faces financial challenges, including significant net losses and limited cash, suggesting potential future fundraisings. The company is exploring apitegromab's potential in obesity treatment, with a Phase 2 study underway, in combo with a GLP-1 agonist drug - results are expected in Q2 2025. Given current valuation and financial risks, I recommend a "Hold" rating, with potential buying opportunities post-approval or pre-obesity study results if the share price dips below $30, I'd suggest. Read the full article on Seeking Alpha

Seeking Alpha • Oct 07

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Summary Apitegromab met the primary endpoint in its phase 3 SAPPHIRE study for spinal muscular atrophy, setting up BLA & MAA filings in Q1 2025. Apitegromab is the first treatment targeting muscle fiber atrophy in SMA, potentially changing the standard of care and offering a competitive edge. Scholar Rock also has apitegromab being explored in a phase 2 study for obesity, with clinical data expected in Q2 2025, presenting another catalyst. The spinal muscular atrophy market in the 7 major markets [7MM] is expected to reach $13 billion by 2034. Read the full article on Seeking Alpha

Seeking Alpha • Jan 12

Scholar Rock: Solid Data And Good Prospects

Summary Scholar Rock's stock price has increased from $6 to $16, indicating increased market interest. Scholar Rock develops apitegromab, a targeted therapy for Spinal Muscular Atrophy (SMA) that inhibits myostatin activation. Phase 2 data shows sustained improvement in motor function for non-ambulatory SMA patients receiving apitegromab. Phase 3 data expected in 4Q 2024. Read the full article on Seeking Alpha

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: SRRK şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: SRRK şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Scholar Rock Holding Piyasaya Karşı Temettü Getirisi

SRRK temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (SRRK)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.4%
Analist tahmini (SRRK) (3 yıla kadar)	0%

Önemli Temettü: SRRK şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, SRRK şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: SRRK şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: SRRK herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Güçlü temettü ödeyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/25 16:18
Gün Sonu Hisse Fiyatı	2026/06/25 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Scholar Rock Holding Corporation 24 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Madhu Kumar	Baird
Etzer Darout	Barclays
Evan Seigerman	BMO Capital Markets Equity Research

Scholar Rock Holding Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Scholar Rock: New Treatment Boost For SMA Patients -- With September PDUFA

Scholar Rock Holding (SRRK) Stock Could Be 14.1% Undervalued On Its SMA Narrative

Consensus revenue estimates decrease by 65%

FDA Accepts Scholar Rock’s Apitegromab BLA With Key Decision Expected September 2026

Independent Director exercised options to buy US$4.2m worth of stock.

Scholar Rock Holding Corporation, Annual General Meeting, Jun 04, 2026

CEO & Chairman of the Board recently sold US$1.5m worth of stock

Scholar Rock Holding Corporation to Report Q1, 2026 Results on May 07, 2026

Consensus revenue estimates decrease by 11%

Scholar Rock Resubmits Biologics License Application For Apitegromab For Treatment Of Children And Adults With Spinal Muscular Atrophy

Muscle-Targeted SMA Therapies And Global Expansion Will Reshape Long-Term Outlook

Price target increased by 9.4% to US$55.07

General Counsel & Corporate Secretary recently sold US$446k worth of stock

Scholar Rock Holding Corporation to Report Q4, 2025 Results on Mar 03, 2026

Chief Scientific Officer exercised options and sold US$350k worth of stock

CEO & Chairman of the Board recently sold US$2.5m worth of stock

Chief Scientific Officer exercised options and sold US$3.3m worth of stock

Scholar Rock Holding Corporation to Report Q3, 2025 Results on Nov 14, 2025

Consensus revenue estimates decrease by 56%

Insider recently bought US$19m worth of stock

Consensus revenue estimates decrease by 10%

Consensus revenue estimates decrease by 20%

Scholar Rock Announces U.S. Food and Drug Administration Issues Complete Response Letter for the Apitegromab Biologics License Application for Patients with Spinal Muscular At Catalent Indiana LLC Fill-Finish Facility

Consensus revenue estimates increase by 43%

Scholar Rock Announces Positive Study Results from the Pivotal Phase 3 Sapphire Trial

Consensus revenue estimates decrease by 25%

New minor risk - Profitability

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 3000E Index

Scholar Rock to Present Comprehensive Update At 2025 Annual Cure Sma Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 Sapphire Trial

Scholar Rock Holding Corporation Announces EMBRAZE Trial Results

Scholar Rock Holding Corporation Announces Appointment of Rebecca Mcleod as Chief Brand Officer

Board Member notifies of intention to sell stock

Consensus revenue estimates fall by 73%

No longer forecast to breakeven

New minor risk - Profitability

Insufficient new directors

Scholar Rock Appoints Vikas Sinha as Chief Financial Officer

Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade

Chief Commercial Officer notifies of intention to sell stock

FDA Grants Priority Review for Biologics License Application (BLA) and Ema Accepts Marketing Authorisation Application (MAA) for Apitegromab as A Treatment for Spinal Muscular Atrophy

Scholar Rock Holding Corporation, Annual General Meeting, May 22, 2025

Scholar Rock Holding Corporation Announces Executive Changes

Scholar Rock Holding Corporation Announces Executive Changes

Senior Advisor exercised options and sold US$2.5m worth of stock

Forecast to breakeven in 2027

New major risk - Shareholder dilution

President recently sold US$677k worth of stock

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

Scholar Rock Announces the Appointment of Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

President recently sold US$986k worth of stock

Scholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High

Price target increased by 15% to US$42.88

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million.

Price target increased by 11% to US$29.75

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

New major risk - Financial position

Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

CFO, COO & Treasurer recently sold US$85k worth of stock

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

Price target increased by 8.1% to US$26.25

New minor risk - Share price stability

New major risk - Financial position

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Scholar Rock: Solid Data And Good Prospects

CFO, COO & Treasurer notifies of intention to sell stock

Senior VP & Head of Research recently sold US$295k worth of stock